

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box (430) Alexandria, Virginia 22313-1450 www.orupo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/826,105	04/16/2004	Mark D. Soll	MER 04-024	9262	
7590 08/12/2008 Judy JARECKI-BLACK, Ph.D., J.D.			EXAM	EXAMINER	
3239 Satellite Blvd.			LEVY, NEIL S		
Duluth, GA 30	0096		ART UNIT	PAPER NUMBER	
			1615		
			MAIL DATE	DELIVERY MODE	
			08/12/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/826,105 SOLL ET AL. Office Action Summary Examiner Art Unit NEIL LEVY 1615 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status Responsive to communication(s) filed on 4/28/08. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-36 is/are pending in the application. 4a) Of the above claim(s) 1-25.30-32 and 34-36 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 26-29 and 33 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-36 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date.

Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO/S6/08) Paper No(s)/Mail Date _

Notice of Informal Patent Application

6) Other:

Art Unit: 1615

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim1-25, 30-32 and 34-36 stand withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention and species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 44/28/08

Claims 1-7, 35 and 36 are not supported as claimed, and are not of the premix formulations.

Note is taken of common ownership of 72622141 and failure of ALIG as anticipatory. See new rejections.

Claim Rejections - 35 USC § 103

Claims 26-29,33 stand rejected under 35 U.S.C. 103(a) as being unpatentable over ALIG et al 6518296 in view of CLEVERLY et al and STETTER et al.

ALIG shows the instant compound (Table 14, R2=CF3, R3=NH2) in compositions of the instant claimed formulation components, paraffin, oils, and organic solvents (column 24, top), with corn cobs and meals (column 24, lines 16-18) with surfactants (lines 18-23). Additional actives include avermectins (column 26, bottom). Oral formulations for cattle, pets and other animals are at column 29, top. Alig does notg haave all claimed comonenets, as applicant points out.

CLEVERLY also provides fipronil derivatives [0088] and shows fipronil and avermactin [0062, 0065] of the instant formulations inclusive of a corn cob or corn meal [0021] filler, pH modifier, antioxidant, and surfactant [0054-0060]. Tablet forms include waxes (claim 53) [0189].

Art Unit: 1615

STETTER shows similar compounds to the fipronil (column 1, 2) derivatives to be useful in feed premix forms-medicated feed (column 7, lines 55-57). Additional actives included are the avermectins (column 11, lines 11-18). Formulations include surfactants (column 8, top), waxes (column 8, line 30), antioxidants (column 9, top), carriers of calcium carbonate, silicas, grains and cereal meals, com cob (column 10, top).

ALIG provides the instant actives, applicable in feed, but does not show wax antioxidant and pH modifiers. These are standard formulation ingredients, and are shown in the secondary references.

.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to utilize pest control means, to use any of art recognized means, as of the ALIG formulations, modified as desired to permit application in feeds for animals.

It would be obvious to vary the form of the formulations to optimize the effect desired, depending upon the particular species and application method of interest, reduction of toxicity, cost minimization, enhanced, and prolonged, or synergistic effects.

Applicant has not provided any objective evidence of nonobvious or unexpected results that the administration of the particular ingredients'combination or formulation provides any greater or different level of prior art expectation as claimed, and the use of ingredient for the functionality for which they are known to be used is not basis for patentability.

Art Unit: 1615

Double Patenting

Claim26 -29,33 ARE provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim1,4,5,8-10,13,15-21,23-29,33 of copending Application No. 11580731. Although the conflicting claims are not identical, they are not patentably distinct from each other because the 11/580731 would anticipate the instant claimed invention.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPC2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPC 645 (Fed. Cir. 1985); In re Van Omum, 686 F.2d 937, 214 USPC 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPC 944 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3,73(b).

Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM EST..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, MICHAEL WOODWARD can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NEIL LEVY/ Primary Examiner, Art Unit 1615